Literature DB >> 3168947

Biliary dyskinesia.

W J Hogan1, J E Geenen.   

Abstract

Delivery of bile into the duodenum involves a series of complex interrelationships between hepatic secretion of bile and pressure differentials generated within the gallbladder, cystic duct and sphincter of Oddi. Theoretically, functional disorders of bile flow may arise from a disturbance of any one of the above factors. A brief review of our present knowledge of the physiology of bile flow and the spectrum of functional biliary tract disorders will be outlined to help explain possible factors which may be involved in biliary tract dysmotility disturbances. The sphincter of Oddi (SO) mechanism is dedicated to maintaining a low pressure system within the hepatic ducts which allows hepatic secretion to proceed irrespective of bile flow rate. Partial obstruction at the SO segment can give rise to intermittent or persistent upper abdominal pain. We classify sphincter of Oddi (SO) motor dysfunction into two broad categories: 1. SO stenosis: defined as a structural narrowing of part or all of the SO segment, and 2) SO dyskinesia: defined as a primary disorder of SO tonic/phasic motor activity. We have attempted to deal with an overlap in etiology of SO motor dysfunction by developing patient group classifications. Biliary I-patients with biliary-type pain, abnormal liver function tests (SGOT; al PO4 greater than 2 x normal) documented on 2 or more occasions, delayed drainage of ERCP contrast greater than 45 min, and dilated CBD greater than 12 mm diameter; Biliary II-patients with biliary-type pain but only 1 or 2 of the above criteria; Biliary III-patients with only biliary-type pain and no other abnormalities. A few of these patients may have primary SO dyskinesia.

Entities:  

Mesh:

Year:  1988        PMID: 3168947     DOI: 10.1055/s-2007-1018172

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  66 in total

Review 1.  Efficacy of biliary scintigraphy in suspected sphincter of Oddi dysfunction.

Authors:  S Jagannath; A N Kalloo
Journal:  Curr Gastroenterol Rep       Date:  2001-04

2.  Is hepatobiliary scintigraphy insensitive for the diagnosis of sphincter of Oddi dysfunction?

Authors:  L Madácsy; A Szepes; V Bertalan; P Funch-Jensen
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

3.  Diagnostic and therapeutic ERCP: a large single centre's experience.

Authors:  R J Farrell; N Mahmud; N Noonan; D Kelleher; P W Keeling
Journal:  Ir J Med Sci       Date:  2001 Jul-Sep       Impact factor: 1.568

4.  Challenges in planning and initiating a randomized clinical study of sphincter of Oddi dysfunction.

Authors:  Peter B Cotton; Valerie Durkalski; Kyle B Orrell; Olga Brawman-Mintzer; Douglas A Drossman; C Mel Wilcox; Patrick D Mauldin; Grace H Elta; Paul R Tarnasky; Evan L Fogel; Sanjay B Jagganath; Richard A Kozarek; Martin L Freeman; Joseph Romagnuolo; Patricia R Robuck
Journal:  Gastrointest Endosc       Date:  2010-11       Impact factor: 9.427

Review 5.  Biliary scintigraphy versus sphincter of Oddi manometry in patients with post-cholecystectomy pain: is it time to disregard the scan?

Authors:  James Toouli
Journal:  Curr Gastroenterol Rep       Date:  2005-05

Review 6.  Endoscopy in the diagnosis and management of motility disorders.

Authors:  Yael Kopelman; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2011-02-01       Impact factor: 3.199

7.  Functional biliary disorders: the Rome III experience.

Authors:  Walter J Hogan
Journal:  Curr Gastroenterol Rep       Date:  2007-04

Review 8.  The investigation of unexplained biliary dilatation.

Authors:  Alan Coss; Robert Enns
Journal:  Curr Gastroenterol Rep       Date:  2009-04

9.  Biliary and gallbladder dyskinesia.

Authors:  Josh George; John Baillie
Journal:  Curr Treat Options Gastroenterol       Date:  2007-08

10.  Endoscopic sphincterotomy for stenosis of the sphincter of Oddi.

Authors:  C Sugawa; D H Park; C E Lucas; D Higuchi; K Ukawa
Journal:  Surg Endosc       Date:  2001-07-05       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.